ClinicalTrials.gg
RecruitingNCT06891144Updated Mar 24, 2025

Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy

An observational study in AML, Adult, sponsored by French Innovative Leukemia Organisation. Recruiting at 27 sites in France. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by French Innovative Leukemia Organisation · Observational

How we know

From the registry’s dates

  • Started Jan 2015; still recruiting 11 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,000
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Leukemia, Myeloid, Acute by French Innovative Leukemia Organisation — 4 open to participants now, 7 under way, none of them phase 3. Leukemia, Myeloid, Acute · French Innovative Leukemia Organisation.

Started
2015
the only one that year
Observational
5 of 16
2 open now
Registered
15th of 16
by date

Among the 16 studies in Leukemia, Myeloid, Acute by French Innovative Leukemia Organisation, this one is the only one that started in 2015, is one of 5 observational ones, and was the 15th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 16 studies in Leukemia, Myeloid, Acute by French Innovative Leukemia Organisation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Leukemia, Myeloid, Acute by French Innovative Leukemia Organisation, or all of them as a file.
02

Study summary

This observational epidemiological study targets patients aged 60 and over with de novo or secondary acute myeloblastic leukemia suitable for intensive receive intensive induction therapy as defined by the group. The main aim of the study is to determine the epidemiological characteristics of AML patients, both clinically and biologically, and to correlate these to their outcome. The incidence of AML increases with age, exponentially after the age of 50, giving a median age at diagnosis of close to 70 years, with over half of patients half of patients are over 60 at diagnosis. The principle of treatment as in younger patients, is based on trying to achieve complete remission (CR). remission (CR). Observed complete remission rates range from 38 to 70%. Long-term survival of elderly subjects remains limited, at around 10 to 15%, despite the various types of consolidation tried out in recent years.

years. However, intensive chemotherapy remains the preferred option for initial treatment of these hematological diseases when general condition and comorbidities allow. As shown by Swedish registry studies, it is associated with improved life expectancy.

The proportion of patients who can receive intensive initial treatment is not well known in France, probably varies widely from one region to another, and certainly decreases with increasing age. Only the registry studies currently underway will enable us to assess this precisely.

03

Conditions studied

  • AML, Adult
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients aged 60 and over with de novo or secondary acute myeloblastic leukemia suitable for intensive induction therapy, as defined by the group's recommendations

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 60 and over
  • Patients with previously untreated de novo or secondary AML
  • Patients suitable for standard intensive treatment
  • Patients who have read the information document and agreed to the collection of data concerning them (signature of ).

Exclusion criteria

Exclusion Criteria:

  • Patients with AML 3
  • Patients with severe, uncontrolled infection at the time of inclusion
  • Patients with psychiatric or social disorders that will prevent compliance with the protocol
  • Patients without health insurance (affiliation to a social security scheme)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. describe the initial characteristics of Acute myeloid leukemia (AML) in patients aged 60 years and older

    Values for leukocytosis, blasts, neutrophils, and platelets (in /mm3)

    Time frame: at diagnosis (from first results related to AML until AML diagnosis) 3 months

  2. describe the initial characteristics of Acute myeloid leukemia (AML) in patients aged 60 years and older

    the cytogenetic pronosis according ELN criteria

    Time frame: at diagnosis (from first results related to AML until AML diagnosis) 3 months

  3. Describe first line AML treatment received

    type of treatment

    Time frame: 12 months

  4. characterize the Overall survival (OS)

    defined as the time from date of initiation of chemotherapy to date of death due to any cause. Patients still alive or lost to follow up will be censored at the time they were last known to be alive

    Time frame: 5 years

07

Study locations

27 of 27 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2015 (actual). Primary completion is estimated for Jan 2030, 180 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Mar 24, 2025
StartActual
Jan 6, 2015
Primary completionEst.
Jan 6, 2030
CompletionEst.
Jan 6, 2031
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06891144
Lead sponsor
French Innovative Leukemia Organisation
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Jan 6, 2015
Primary completion
Jan 6, 2030 (estimated)
Completion
Jan 6, 2031 (estimated)
Last update
Mar 24, 2025

Study contacts

Ariane Mineur
Contact
ariane.mineur@chu-bordeaux.fr
+33 (5)57 62 31 08
Arnaud Pigneux, Prof
study chair · French Innovative Leukemia Organization

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion